# A Study in Participants With Moderate to Severe Rheumatoid Arthritis

> **NCT01711359** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 588 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Baricitinib
- **DRUG:** Methotrexate
- **DRUG:** Baricitinib Placebo
- **DRUG:** MTX Placebo
- **DRUG:** Folic Acid

## Key facts

- **NCT ID:** NCT01711359
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2015-02
- **Final completion:** 2015-08
- **Target enrollment:** 588 (ACTUAL)
- **Last updated:** 2019-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01711359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01711359, "A Study in Participants With Moderate to Severe Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01711359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*